Literature DB >> 15343348

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

S Böttcher1, M Ritgen, C Pott, M Brüggemann, T Raff, S Stilgenbauer, H Döhner, P Dreger, M Kneba.   

Abstract

The clinically most suitable method for minimal residual disease (MRD) detection in chronic lymphocytic leukemia is still controversial. We prospectively compared MRD assessment in 158 blood samples of 74 patients with CLL after stem cell transplantation (SCT) using four-color flow cytometry (MRD flow) in parallel with consensus IgH-PCR and ASO IgH real-time PCR (ASO IgH RQ-PCR). In 25 out of 106 samples (23.6%) with a polyclonal consensus IgH-PCR pattern, MRD flow still detected CLL cells, proving higher sensitivity of flow cytometry over PCR-genescanning with consensus IgH-primers. Of 92 samples, 14 (15.2%) analyzed in parallel by MRD flow and by ASO IgH RQ-PCR were negative by our flow cytometric assay but positive by PCR, thus demonstrating superior sensitivity of RQ-PCR with ASO primers. Quantitative MRD levels measured by both methods correlated well (r=0.93). MRD detection by flow and ASO IgH RQ-PCR were equally suitable to monitor MRD kinetics after allogeneic SCT, but the PCR method detected impending relapses after autologous SCT earlier. An analysis of factors that influence sensitivity and specificity of flow cytometry for MRD detection allowed to devise further improvements of this technique.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343348     DOI: 10.1038/sj.leu.2403478

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Authors:  Aaron C Logan; Hong Gao; Chunlin Wang; Bita Sahaf; Carol D Jones; Eleanor L Marshall; Ismael Buño; Randall Armstrong; Andrew Z Fire; Kenneth I Weinberg; Michael Mindrinos; James L Zehnder; Scott D Boyd; Wenzhong Xiao; Ronald W Davis; David B Miklos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Assessing minimal residual disease in chronic lymphocytic leukemia.

Authors:  Andy C Rawstron; Peter Hillmen
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 3.  Eradication of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Carmen Diana Schweighofer; Michael Hallek; Clemens-Martin Wendtner
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

4.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

5.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

6.  An automated high-throughput counting method for screening circulating tumor cells in peripheral blood.

Authors:  Mengxia Zhao; Perry G Schiro; Jason S Kuo; Karen M Koehler; Daniel E Sabath; Viorica Popov; Qinghua Feng; Daniel T Chiu
Journal:  Anal Chem       Date:  2013-02-06       Impact factor: 6.986

7.  Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network.

Authors:  Wolfram Klapper; Eva Hoster; Olaf Determann; Ilske Oschlies; Jeroen van der Laak; Françoise Berger; Heinz Wolfram Bernd; José Cabeçadas; Elias Campo; Sergio Cogliatti; Martin Leo Hansmann; Philip M Kluin; Roman Kodet; Yuri A Krivolapov; Christoph Loddenkemper; Harald Stein; Peter Möller; Thomas E F Barth; Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Stefano Pileri; Elisabeth Ralfkiaer; Grzegorz Rymkiewicz; Johan H van Krieken; Hans Heinrich Wacker; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Journal:  J Hematop       Date:  2009-06-16       Impact factor: 0.196

8.  First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.

Authors:  Carmen Diana Schweighofer; Clemens-Martin Wendtner
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Sabrina Uhrmacher; Felix Erdfelder; Karl-Anton Kreuzer
Journal:  Adv Hematol       Date:  2010-09-20

10.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Mohamed L Sorror; Barry E Storer; Brenda M Sandmaier; Michael Maris; Judith Shizuru; Richard Maziarz; Edward Agura; Thomas R Chauncey; Michael A Pulsipher; Peter A McSweeney; James C Wade; Benedetto Bruno; Amelia Langston; Jerald Radich; Dietger Niederwieser; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.